Can a gastrointestinal pathologist identify microsatellite instability in colorectal cancer with reproducibility and a high degree of specificity?

详细信息    查看全文

• 作者：Eli Brazowski (13)
  Paul Rozen (23) prozen@012.net.il
  Sara Pel (2)
  Ziona Samuel (2)
  Irit Solar (1)
  Guy Rosner (2)
• 关键词：Crohn’ ; s ; like &#8211 ; Lynch syndrome &#8211 ; Tumor ; infiltrating lymphocytes &#8211 ; Microsatellite instability &#8211 ; Scoring &#8211 ; Specificity
• 刊名：Familial Cancer
• 出版年：2012
• 出版时间：June 2012
• 年：2012
• 卷：11
• 期：2
• 页码：249-257
• 全文大小：524.3 KB
• 参考文献：1. Jass JR (2000) Pathology of hereditary nonpolyposis colorectal cancer. Ann NY Acad Sci 910:62–73; discussion 73–74. Review
  2. Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, Zhang XM, Markowitz AJ, Nafa K, Guillem JG, Wong WD, Gerald WL, Klimstra DS (2003) Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 27:1407–1417
  3. Truta B, Chen YY, Blanco AM, Deng G, Conrad PG, Kim YH, Park ET, Kakar S, Kim YS, Velayos F, Sleisenger MH, Terdiman JP (2008) Tumor histology helps to identify Lynch syndrome among colorectal cancer patients. Fam Cancer 7:267–274
  4. Polydorides AD, Mukherjee B, Gruber SB, McKenna BJ, Appelman HD, Greenson JK (2008) Adenoma-infiltrating lymphocytes (AILs) are a potential marker of hereditary nonpolyposis colorectal cancer. Am J Surg Pathol 32:1661–1666
  5. Sanchez JA, Vogel JD, Kalady MF, Bronner MP, Skacel M, Church JM (2008) Identifying Lynch syndrome: we are all responsible. Dis Colon Rectum 51:1750–1756
  6. Overbeek LI, Hermens RP, van Krieken JH, Adang EM, Casparie M, Nagengast FM, Ligtenberg MJ, Hoogerbrugge N, MIPA study group (2010) Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial. Virchows Arch 456:653–659
  7. Jenkins MA, Hayashi S, O’Shea AM, Burgart LJ, Smyrk TC, Shimizu D, Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, Barker MA, Baron JA, Casey GR, Dowty JG, Giles GG, Limburg P, Newcomb P, Young JP, Walsh MD, Thibodeau SN, Lindor NM, Lemarchand L, Gallinger S, Haile RW, Potter JD, Hopper JL, Jass JR, Colon Cancer Family Registry (2007) Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 133:48–56
  8. Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, Ben-Izhak O, Cohen HI, Trougouboff P, Bejhar J, Sova Y, Pinchev M, Rennert G, Gruber SB (2009) Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 33:126–133
  9. Hyde A, Fontaine D, Stuckless S, Green R, Pollett A, Simms M, Sipahimalani P, Parfrey P, Younghusband B (2010) A histology-based model for predicting microsatellite instability in colorectal cancers. Am J Surg Pathol 34:1820–1829
  10. Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC, O’Connell MJ, North Central Cancer Treatment Group (2010) Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer 116:1691–1698
  11. Rom谩n R, Verd煤 M, Calvo M, Vidal A, Sanjuan X, Jimeno M, Salas A, Autonell J, Trias I, Gonz谩lez M, Garc铆a B, Rod贸n N, Puig X (2010) Microsatellite instability of the colorectal carcinoma can be predicted in the conventional pathologic examination. A prospective multicentric study and the statistical analysis of 615 cases consolidate our previously proposed logistic regression model. Virchows Arch 456:533–541
  12. Chubak B, Heald B, Sharp RR (2011) Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genet Med 13:356–360
  13. Washington MK, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons PL, Halling K, Frankel W, Jessup J, Kakar S, Minsky B, Nakhleh R, Compton CC, Members of the Cancer Committee, College of American Pathologists (2009) Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 133:1539–1551
  14. de la Chapelle A, Hampel H (2010) Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28:3380–3387
  15. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-Fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863–875
  16. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2009) Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35–41
  17. Schofield L, Watson N, Grieu F, Li WQ, Zeps N, Harvey J, Stewart C, Abdo M, Goldblatt J, Iacopetta B (2009) Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 124:1097–1102
  18. Wright DM, Arnold JL, Parry B, Hulme-Moir M, Winship IM, Parry S (2011) Immunohistochemistry to detect hereditary nonpolyposis colorectal cancer in young patients: the 7-year Auckland experience. Dis Colon Rectum 54:552–558
  19. Overbeek LI, Hermens RP, van Krieken JH, Adang EM, Casparie M, Nagengast FM, Ligtenberg MJ, Hoogerbrugge N, MIPA study group (2010) Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial. Virchows Arch 456:653–659
  20. Manders P, Spruijt L, Kets CM, Willems HW, Bodmer D, Hebeda KM, Nagtegaal ID, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N (2011) Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome. Eur J Cancer 47:1407–1413
  21. Lynch PM (2011) How helpful is age at colorectal cancer onset in finding hereditary nonpolyposis colorectal cancer? (Comment). Clin Gastroenterol Hepatol 9:458–460
  22. Morrison J, Bronner M, Leach BH, Downs-Kelly E, Goldblum JR, Liu X (2011) Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: From the revised Bethesda guidelines to a universal approach. Scand J Gastroenterol 46:1340–1348
  23. P茅rez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Pay谩 A, Brea A, Egoavil CM, Castillejo A, Barber谩 VM, Bessa X, Xicola RM, Rodr铆guez-Soler M, S谩nchez-Fort煤n C, Acame N, Castellv铆-Bel S, Pi帽ol V, Balaguer F, Bujanda L, De-Castro ML, Llor X, Andreu M, Carracedo A, Soto JL, Castells A, Jover R. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut (in press)
  24. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA (2011) Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155:69–79
• 作者单位：1. Department of Pathology, Tel Aviv Medical Center, 6 Weizmann Street, 64239 Tel Aviv, Israel2. Department of Gastroenterology, Tel Aviv Medical Center, 6 Weizmann Street, 64239 Tel Aviv, Israel3. Tel Aviv University, Tel Aviv, Israel
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Human Genetics
  Epidemiology
  
• 出版者：Springer Netherlands
• ISSN：1573-7292

文摘

Clinical features usually initiate evaluation for Lynch Syndrome (LS) but some colorectal cancer (CRC) histopathology findings are compatible with high microsatellite instability (MSI-H) that also occurs in LS. This led to the suggestion that pathologists request MSI analysis, which is an expensive addition to routine histology. We aimed to see if a Gastrointestinal Pathologist could identify MSI-H features with reproducibility and high (95%) specificity (MSI-H 95%). Histopathology of all CRCs received during 2005 and 4 MSI-H controls were scored using 2 published methods, “MsScore” and “PathScore”. MSI analysis was performed on CRCs scored by either method as probable MSI-H 95% and results compared. To examine reproducibility of histopathology, 100 coded slides, including 25 scored MSI-H 95% and 75 scored low, were re-examined to now identify those needing MSI analysis. Costs were evaluated for identifying MSI-H with or without scoring. All 227 CRCs were scored for possible MSI-H 95%; 24 had high scores and MSI analysis. DNA analysis proved 14 MSI-H, PathScore identified 13 (95%), MsPath identified 9 (64%), histopathology alone identified 7 (50%). Reproducibility for identifying histopathology characteristics of MSI-H at re-examination, without scoring, was “moderate agreement” (Kappa statistic = 0.4615). Costs for identifying MSI-H by PathScore were the lowest, $436/identification. Conclusions; PathScore identified the most proven MSI-H CRCs at lowest cost and even an experienced gastrointestinal pathologist has difficulties identify MSI-H without scoring. So, scoring can be facilitated by a computerized evaluation form for routine CRC histology, prompting score computation and recommendation for MSI analysis with high specificity.